Saturday 17 October 2026
Export SYBX’s income statement to Excel — free account
Synlogic, Inc.
SYBX Healthcare Biotechnology
Synlogic, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8,000.00, down 99.8% from fiscal 2023. In the quarter to June 2026, EPS was flat and free cash flow fell 277.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.00
0.08
−7.41%
Follow SYBX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
9.02 | 6.86 | 4.09 | 2.50 | |
Current Ratio |
9.19 | 7.08 | 4.30 | 2.65 | |
Net Debt/EBITDA |
13.03 | 10.69 | 10.93 | 15.73 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.70 | (0.83) | (0.61) | 0.62 | |
Capex/Depreciation |
— | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.07) | (0.05) | (0.07) | (0.12) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.05) | (0.07) | (0.12) | |
Cash per Share |
1.06 | 1.14 | 1.19 | 1.27 | |
Shareholders Equity per Share |
0.97 | 1.01 | 0.96 | 0.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.97 | 1.01 | 0.96 | 0.84 | |
Free Cash Flow |
(0.92) | (0.56) | (0.92) | (1.44) | |
Working Capital |
11.97 | 12.50 | 11.81 | 10.28 | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
11.97 | 12.50 | 11.81 | 10.28 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.06 | 0.14 | 0.13 | 0.14 | |
Average Assets |
15.42 | 16.29 | 17.64 | 18.66 | |
Average Common Equity |
12.31 | 12.82 | 12.31 | 11.72 |
Columns are period end dates